Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | PPIA | P62937 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26121308 | 0.98 | KMT2A (0.38) | KMT2AKDM4EMAPTMEN1MAPK1 | |
| SCHEMBL23120812 | 0.91 | KMT2A (0.33) | KMT2AKDM4EMAPTMEN1MAPK1 | |
| SCHEMBL21624845 | 0.91 | KMT2A (0.33) | KMT2AKDM4EMAPTMEN1MAPK1 | |
| SCHEMBL1820679 | 0.88 | MAPT (0.39) | KMT2AMAPTMEN1MAPK1ALDH1A1 | |
| SCHEMBL22962223 | 0.88 | MAPT (0.38) | KMT2AKDM4EMAPTMEN1MAPK1 | |
| SCHEMBL391041 | 0.85 | KMT2A (0.43) | KMT2AKDM4EMEN1MAPK1GHSR | |
| SCHEMBL2781817 | 0.85 | OPRM1 (0.42) | KMT2AKDM4EMEN1MAPK1ALDH1A1 | |
| SCHEMBL1350921 | 0.85 | MAPT (0.47) | KMT2AMAPTMEN1MAPK1ALDH1A1 | |
| SCHEMBL4094284 | 0.85 | MAPT (0.44) | KMT2AMAPTMEN1MAPK1ALDH1A1 | |
| SCHEMBL28269495 | 0.84 | KMT2A (0.37) | KMT2AKDM4EMEN1MAPK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565585-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | Bristol-Myers Squibb Company (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250092091-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE LIGANDS | Humanwell Pharmaceutical US | 2025-03-20 | — | — | US | disclosed |
| US-12252495-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2025-03-18 | — | — | US | disclosed |
| US-12215173-B2 | Kappa opioid receptor peptide amide ligands | HUMANWELL PHARMACEUTICAL US, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-11998545-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-04 | — | — | US | disclosed |
| EP-3521301-B1 | POLYAMIDE COMPOUND AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024030968-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030968-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2008054702-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008054702-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2005047253-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
| EP-1163242-A2 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | Boehringer Ingelheim Pharma KG (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055162-A2 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-21 | — | — | WO | disclosed |
| EP-0231087-B1 | HEPTANOYL-GLU-ASP-ALA-AMINO ACID IMMUNOSTIMULANTS | PFIZER INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| US-4851388-A | Heptanoyl-glu-asp-ala-amino acid immunostimulants | PFIZER INC. (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0231087-A2 | Heptanoyl-glu-asp-ala-amino acid immunostimulants | PFIZER INC. (US) | 1987-08-05 | — | — | EP | disclosed |
| WO-1987004440-A1 | HEPTANOYL-GLU-ASP-ALA-AMINO ACID IMMUNOSTIMULANTS | PFIZER INC. (US) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | KMT2A 1343/4885KDM4E 1852/4885MAPT 3725/4885 |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | KMT2A 1343/4885KDM4E 1852/4885MAPT 3725/4885 |
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, CYP11B1 | KMT2A 4520/4885KDM4E 4527/4885MAPT 1580/4885 |
| US-20250092091-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE LIGANDS | OPRK1, OPRL1, OPRD1 | KMT2A 2111/4885KDM4E 3710/4885MAPT 1608/4885 |
| US-11998545-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | KMT2A 1171/4885KDM4E 889/4885MAPT 1769/4885 |
| US-12215173-B2 | Kappa opioid receptor peptide amide ligands | OPRK1, OPRL1, OPRD1 | KMT2A 2111/4885KDM4E 3710/4885MAPT 1608/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | KMT2A 1171/4885KDM4E 889/4885MAPT 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.